T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer

(MedPage Today) — CHICAGO — Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) instead of ramucirumab…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115823

Author :

Publish date : 2025-05-31 12:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer

The Covid Inquiry Podcast: ‘I wasn’t the decision maker’

Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

Related Posts

Major Medical Groups Pushed Out of Role Supporting CDC’s Vaccine Advisors

‘It’s Gonna Be (Ly)me’: Justin Timberlake Brings Attention, Awareness to Disease

ACOG No Longer Accepting Federal Funding, Citing Policy Disputes

States Sue Trump, Say Targeting of Hospitals Over Gender Care in Minors Is Unlawful

Time Your Meals, Tune Your Metabolism

Novel Eye Drops for Age-Related Blurry Vision Win FDA Approval

Major Medical Groups Pushed Out of Role Supporting CDC’s Vaccine Advisors

‘It’s Gonna Be (Ly)me’: Justin Timberlake Brings Attention, Awareness to Disease

ACOG No Longer Accepting Federal Funding, Citing Policy Disputes

States Sue Trump, Say Targeting of Hospitals Over Gender Care in Minors Is Unlawful

Time Your Meals, Tune Your Metabolism

Novel Eye Drops for Age-Related Blurry Vision Win FDA Approval

Bone Health in Duchenne Muscular Dystrophy

Could we get quantum spookiness even without entanglement?

Categories

Archives